Cutaneous Melanoma Active Not Recruiting Phase 2 Trials for Ipilimumab (DB06186)

IndicationStatusPhase
DBCOND0040978 (Cutaneous Melanoma)Active Not Recruiting2
clinicaltrials.gov IdentifierTitlePurposeDrugs
NCT02519322Neoadjuvant and Adjuvant Checkpoint BlockadeTreatment